BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34689002)

  • 1. Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database.
    Bassompierre A; Dalac S; Dreno B; Neidhardt EM; Maubec E; Capelle C; Andre F; Behal H; Dziwniel V; Bens G; Leccia MT; Meyer N; Granel-Brocard F; Beylot-Barry M; Dereure O; Basset-Seguin N; Mortier L
    ESMO Open; 2021 Dec; 6(6):100284. PubMed ID: 34689002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.
    Herms F; Lambert J; Grob JJ; Haudebourg L; Bagot M; Dalac S; Dutriaux C; Guillot B; Jeudy G; Mateus C; Monestier S; Mortier L; Poulalhon N; Prey S; Robert C; Vabres P; Lebbe C; Meyer N; Basset-Seguin N
    J Clin Oncol; 2019 Dec; 37(34):3275-3282. PubMed ID: 31609670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Experience of Vismodegib in Advanced Basal Cell Carcinoma at a Canadian Cancer Center.
    Tong J; Mitchell B; Roth K; Logan D; Ernst S
    J Cutan Med Surg; 2022; 26(2):143-148. PubMed ID: 34663118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
    Mannino M; Piccerillo A; Fabbrocini G; Quaglino P; Argenziano G; Dika E; Ascierto PA; Pellacani G; Longo C; Fargnoli MC; Bianchi L; Calzavara-Pinton P; Zalaudek I; Fava P; Scalvenzi M; Bocchino E; Di Stefani A; Peris K;
    Dermatology; 2023; 239(6):868-876. PubMed ID: 37311439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?
    Alfieri S; Romanò R; Marceglia S; De Giorgi V; Peris K; Sollena P; Piccerillo A; Moro R; Gualdi G; Ascierto PA; Palla M; Paone M; Eibenschutz L; Spagnolo F; Queirolo P; Filippini DM; Cavalieri S; Resteghini C; Bergamini C; Manocchio A; Licitra L; Bossi P
    Oncologist; 2024 May; 29(5):e699-e707. PubMed ID: 38127280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
    Leavitt E; Lask G; Martin S
    Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Basset-Seguin N
    Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
    Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
    BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
    Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
    Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: An Updated Systematic Review and Meta-analysis (2009-2022).
    Nguyen A; Xie P; Litvinov IV; Lefrançois P
    Am J Clin Dermatol; 2023 May; 24(3):359-374. PubMed ID: 36795228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center.
    Ayén-Rodríguez A; Linares-González L; Llamas-Segura C; Almazán-Fernández FM; Ruiz-Villaverde R
    Int J Environ Res Public Health; 2023 May; 20(10):. PubMed ID: 37239551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
    Mesti T; Sever M; Ocvirk J
    Dermatology; 2023; 239(1):158-164. PubMed ID: 35896082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
    Danial C; Sarin KY; Oro AE; Chang AL
    Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
    Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
    JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors.
    Dessinioti C; Plaka M; Soura E; Mortaki D; Papaxoinis G; Gogas H; Stratigos AJ
    Oncologist; 2019 Aug; 24(8):e755-e764. PubMed ID: 31073024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study.
    Ruiz-Salas V; Podlipnik S; Sandoval-Clavijo A; Sanmartin-Jiménez O; Bernia-Petit E; Bonfill-Ortí M; Bassas-Freixas P; Yebenes-Marsal M; Flórez-Menéndez Á; Solá-Ortigosa J; Just-Sarobé M; Aguayo-Ortiz R; Masferrer I Niubó E; Quintana-Codina M; Deza G; Jaka A; Fuentes MJ; Cañueto J; Toll A
    Dermatology; 2023; 239(5):685-693. PubMed ID: 37257423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
    Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
    J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.